Ketamine as an Analgesic
Ketamine was first developed and approved as an anesthetic agent, and its analgesic properties are fundamental to its pharmacology — not secondary benefits. Blocking NMDA receptors reduces central sensitization, interrupts the "wind-up" phenomenon that amplifies chronic pain, and modulates opioid receptor systems in ways that make it valuable for pain conditions that respond poorly to conventional analgesics.
For patients with chronic neuropathic pain, central sensitization syndromes, or opioid-refractory pain, ketamine troches represent an accessible, home-based option in a larger pain management strategy. Our guide on troche dosage for pain covers specific dosing protocols.
How Ketamine Works for Chronic Pain
NMDA Receptor Blockade and Wind-Up
Chronic pain often involves "central sensitization" — a state in which the nervous system becomes hypersensitized to pain signals, amplifying and perpetuating pain beyond what the original tissue injury would predict. This sensitization is mediated largely by NMDA receptors in the spinal cord dorsal horn.
Repeated or intense pain signaling activates dorsal horn NMDA receptors in a process called "wind-up" — each subsequent pain signal produces a larger neuronal response than the last. Ketamine blocks these NMDA receptors, interrupting wind-up and reducing central sensitization. This explains why ketamine can provide pain relief that outlasts its duration in the bloodstream — the neuroplastic changes it induces in pain processing circuits may persist for days to weeks after the drug has cleared.
Opioid Receptor Interaction
Ketamine binds to opioid receptors (particularly sigma and mu receptors) as part of its analgesic mechanism. Additionally, ketamine can reverse opioid-induced hyperalgesia — the paradoxical increase in pain sensitivity that develops with long-term opioid use. For patients on chronic opioid therapy who have developed tolerance or hyperalgesia, ketamine may restore opioid efficacy and allow dose reduction.
Anti-Inflammatory Effects
Ketamine has demonstrated anti-inflammatory effects at the cellular level, reducing the production of pro-inflammatory cytokines that contribute to pain sensitization in conditions like CRPS and fibromyalgia.
Conditions Most Likely to Respond
Complex Regional Pain Syndrome (CRPS)
CRPS is a chronic, severe pain condition that typically develops in a limb after injury and is characterized by burning pain, allodynia, and autonomic changes. Central sensitization is a core feature. Ketamine has the strongest evidence base for CRPS among all chronic pain conditions, with multiple open-label studies and some controlled trials demonstrating significant pain reduction, particularly with high-dose IV protocols.
Troche-based protocols for CRPS typically use lower doses than IV infusion protocols but can provide meaningful supplemental pain relief and functional improvement as part of a multimodal management approach.
Fibromyalgia
Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, and tenderness without identifiable tissue pathology. Central sensitization is the dominant mechanism. Ketamine's effects on central pain processing make it a rational treatment, and several studies have demonstrated pain reduction and improved function in fibromyalgia patients receiving ketamine.
Troche doses for fibromyalgia are typically in the low to moderate range (50 to 200 mg), with the goal of modulating central pain without necessarily producing the more pronounced dissociative effects seen in psychiatric protocols.
Neuropathic Pain
Neuropathic pain — arising from damage or dysfunction of the nervous system rather than tissue injury — responds poorly to traditional analgesics but often responds to NMDA receptor antagonists. Ketamine troches have been used for:
- Diabetic peripheral neuropathy
- Post-herpetic neuralgia
- Chemotherapy-induced peripheral neuropathy
- Spinal cord injury pain
- Phantom limb pain
Clinical outcomes in neuropathic pain with low-dose ketamine are generally positive, though the evidence is largely from case series and small trials.
Opioid-Refractory Pain
Patients whose chronic pain has become inadequately controlled despite opioid therapy — either through tolerance development or opioid-induced hyperalgesia — can benefit from ketamine's ability to reset central sensitization and potentially restore opioid responsiveness.
Migraine
Ketamine has been used in inpatient settings for refractory migraines with some success. Troche-based use for migraine prevention or acute treatment is less established but reported clinically.
Dosing for Chronic Pain: Differences from Psychiatric Protocols
Chronic pain dosing with troches typically differs from mental health protocols:
Lower Doses
Pain management often uses sub-anesthetic, sub-dissociative doses that produce analgesic effects without the pronounced psychoactive experience of psychiatric doses. Typical pain management troche doses range from 50 to 150 mg, compared to the 150 to 400 mg range common in depression protocols.
At these lower doses:
- Patients remain fully functional
- Minimal to no dissociative effects
- Can be used more frequently (daily in some protocols)
- Less risk of significant adverse effects
Frequency
For pain management, sessions may occur more frequently than in psychiatric protocols:
- Low-dose daily dosing: Some providers use troches at 50 to 100 mg daily or most days of the week as analgesic maintenance
- Twice-weekly analgesic dosing: Similar to psychiatric maintenance protocols
- As-needed dosing: Some patients use a low-dose troche when pain flares
The frequency is determined by the pain condition, its natural fluctuation, and patient response.
Sub-Anesthetic vs. Psychedelic Doses
It is worth distinguishing between:
- Sub-dissociative analgesic dosing: Low doses (50 to 100 mg) that provide pain relief without significant altered states — suitable for daytime use
- Full psychedelic/dissociative dosing: Higher doses (200 mg+) that produce the full altered state experience — typically used for psychiatric indications or when the therapeutic experience itself is part of pain management
Some pain patients benefit from periodic full-dose sessions (which address both pain and the psychological burden of chronic illness) combined with more frequent sub-dissociative doses for daily pain control.
Pain and Psychological Comorbidity
Chronic pain and psychiatric conditions are closely intertwined. Depression affects approximately 30 to 50 percent of chronic pain patients; anxiety is similarly prevalent. The "pain catastrophizing" cognitive pattern — excessive focus on pain, helplessness, rumination — amplifies pain experience and disability.
Ketamine's antidepressant and anxiolytic effects, combined with its direct analgesic mechanism, make it particularly well-suited for the common clinical presentation of chronic pain with comorbid depression or anxiety. Treating both simultaneously is a meaningful advantage.
Monitoring Pain Response
Track:
- Pain Numerical Rating Scale (0 to 10) at consistent times daily
- Pain interference: How much does pain interfere with sleep, work, movement, mood?
- Analgesic use: Are you using less rescue medication after ketamine sessions?
- Function: What activities can you do post-session that you couldn't before?
Review these metrics with your provider to guide dose and frequency adjustments.
Limitations and Cautions
Ketamine troches are not appropriate as the sole treatment for chronic pain. They are best used as part of a multimodal pain management approach that may include:
- Physical therapy
- Other pharmacological agents (anticonvulsants, SNRIs, topical agents as appropriate)
- Psychological pain management (CBT for chronic pain, acceptance and commitment therapy)
- Interventional procedures as indicated
The goal of ketamine is to provide a reset of central sensitization and create a window for functional rehabilitation — not to provide indefinite analgesic coverage as a substitute for comprehensive care.
Key Takeaways
- Ketamine blocks NMDA receptors in pain circuits, interrupting wind-up and central sensitization.
- CRPS, fibromyalgia, and neuropathic pain are the best-evidenced indications.
- Pain protocols typically use lower doses (50 to 150 mg) than psychiatric protocols, sometimes daily.
- Sub-dissociative dosing provides analgesia without significant altered states.
- Ketamine works best as part of a multimodal pain management strategy, not as monotherapy.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
- WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches
Share